Fig. 1From: Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisStudy designs of three phase 3 trials of golimumab in patients with a rheumatoid arthritis (GO-FURTHER), b psoriatic arthritis (GO-VIBRANT), and c ankylosing spondylitis (GO-ALIVE)Back to article page